Preexposure prophylaxis (PrEP) use increased between 2013 and 2023, according to a research letter published online Oct. 14 ...

Long-acting injectable PrEP is now to be covered without cost-sharing under Affordable Care Act rules, the Biden ...

HIV Research for Prevention Conference ANALYSIS | SETHI NCUBE | The 5th HIV Research for Prevention Conference (HIVR4P 2024) ...

Gilead has grown to become a leader in the fight against HIV and has announced efforts to improve access to a new, highly ...

Lenacapavir is a long-acting injectable drug that has proven 100 per cent successful in clinical tests and subsequent human ...

Natal, alarming gaps between scientific advancements and community behaviour persist. This article explores the critical need ...

The 5th HIV Research for Prevention Conference (HIVR4P 2024) held in Lima, Peru, marked a significant milestone in the global ...

"Where we are in the HIV epidemic is that we have better tools than ever for both treatment and for ... or a missed opportunity to receive post-exposure prophylaxis, which can reduce the risk ...

Post-exposure Prophylaxis (PEP) Post-exposure prophylaxis (PEP ... Both are combinations of two HIV drugs in a single pill. When taken every day, PrEP can provide a high level of protection against ...

the innovative HIV treatment used in combination with other antiretrovirals and will support efforts to prevent HIV through pre-exposure prophylaxis (PrEP). “Lenacapavir marks an important miles ...